Introduction
S mall proteins as platforms for imaging probe development have attracted significant interest because of their favorable properties (ease of preparation, possible production by chemical synthesis, high affinity and specificity, rapid blood clearance, quick and good tumor accumulation). Most importantly, some of these protein scaffolds have shown great potential for recognizing a variety of biomarkers [1] [2] [3] [4] [5] . Among them, Affibody molecules have recently received significant attention. Affibody is an engineered small protein scaffold with 58-amino acid residues and a three-helix bundle structure, as derived from one of the IgG-binding domains of staphylococcal protein A [4] . Many Affibody binders against desired targets have been identified and selected using phagedisplay technology [4] .
Human epidermal growth factor receptor type 2 (HER2) is a well-established tumor target overexpressed in a wide variety of cancers including breast, ovarian, lung, gastric, and oral cancers [6] [7] [8] . It has been demonstrated as a molecular target for therapeutic intervention, a prognostic indicator of patient survival, and as a predictive marker of response to antineoplastic therapy [6] [7] [8] . Numerous radionuclides including 18 F [9] [10] [11] , 99m Tc [12] [13] [14] [15] , 111 In [16] [17] [18] [19] , 90 Y [20] , 177 Lu [20, 21] , 68 Ga [22] , 125 I [14, [23] [24] [25] , 76 /77/82 Br [26] , and 211 At [27] have been used to label the anti-HER2 Affibody molecules for tumor imaging or radiotherapy. These studies have clearly demonstrated that Affibody molecules are a promising new class of cancer targeting ligands and worthy of further investigation for developing probes for different tumor targets.
Positron emission tomography (PET) imaging has high sensitivity, spatial resolution, and quantification ability, but with relatively higher cost. It is a great modality for imaging different molecular targets and events and is playing an important role in clinical cancer molecular imaging [28, 29] . Therefore, there is a potential demand to develop PET radioisotopes ( 18 F, 64 Cu, 68 Ga, etc.) labeled Affibody molecules for clinical applications. However, radiometal-labeled Affibody proteins have not been well investigated in the literature; only one abstract has reported to use 68 Ga (t 1/2 = 68 min)-labeled Affibody molecule for HER2 imaging to date [22] . Moreover, there is no study to systematically compare the in vivo performance of both monomeric and dimeric Affibodies using the same Affibody clone. Therefore, in this study, the commercially available anti-HER2 Affibody molecules in monomeric (Z HER2:477 ) and dimeric [(Z HER2:477 ) 2 ] forms [23] were site specifically modified at the C terminus cysteine residue with the maleimide-functionalized chelator, 1,4,7,10-tetraazacyclododecane-1,4,7-β max tris (acetic acid)-10-acetate mono (N-ethylmaleimide amide) (Mal-DOTA; compound 3 in Fig. 1 ). The resulting DOTAAffibody bioconjugates were then radiolabeled with the positron emitter 64 Cu (t 1/2 =12.7 h, E þ b max ¼ 656 keV , 19%). The biological properties of the molecular probes were evaluated in nude mice bearing subcutaneous HER2 expression SKOV3 tumors. Subsequently, the ability of 64 Culabeled HER2-binding Affibody proteins to image HER2 expression in living mice was also evaluated using small animal PET.
Materials and Methods

General Aspects
The anti-HER2 imaging agent Affibody molecule Z HER2:477 and a bivalent Affibody protein anti-HER2 unconjugated (Z HER2:477 ) 2 [21] , purity >95% as provided by the vendor) were purchased from Affibody AB (Bromma, Sweden) and used directly for the chemical modification. 1,4,7,10-Tetraazacyclododecane-1,4,7,-tris(t-butylacetate)-1-succinimidyl acetate PF6 salt (or DOTA-mono-NHS-tris(tBu)ester) was purchased from Macrocyclics Inc. (Dallas, TX, USA). Dichloromethane, 2-(tertbutoxycarbonylaminooxy)acetic acid, triethylamine, N-(2-aminoethyl)maleimide-trifluoroacetic acid (TFA) salt, N-hydroxybenzotriazole hydrate (HOBT), 1-ethyl-3- [3-dimethylaminopropyl] carbodiimide (EDC), N-hydroxysuccinimide (NHS), ethyl acetate, dithiothreitol (DTT), tricine, and 4-fluorobenzaldehyde were purchased from Sigma-Aldrich Chemical Co. (St. Louis, MO, USA). Dimethyl sulfoxide (DMSO) and ethyl acetate were purchased from Fisher Scientific (Pittsburgh, PA, USA). All other standard synthesis reagents were purchased from Sigma-Aldrich Chemical Co. (St. Louis, MO, USA). All chemicals were used without further purification. A CRC-15R PET dose calibrator (Capintec Inc., Ramsey, NJ, USA) was used for all radioactivity measurements. Reversed-phase high-performance liquid chromatography (RP-HPLC) was performed on a Dionex Summit HPLC system (Dionex Corporation, Sunnyvale, CA, USA) equipped with a 170U 4-Channel UV-Vis absorbance detector and radioactivity detector (Carroll & Ramsey Associates, model 105S, Berkeley, CA, USA). UV detection wavelengths were 218, 254, and 280 nm for all the experiments. Analytical RP-HPLC columns (Vydac, Hesperia, CA, USA, 218TP510-C18, 10×250 mm) was used for analysis of labeled proteins. The mobile phase was solvent A, 0.1% TFA/H 2 O, and solvent B, 0.1%TFA/acetonitrile. Matrix-assisted laser desorption/ ionization time-of-flight mass spectrometry (MALDI-TOF-MS; model: Perseptive Voyager-DE RP Biospectrometer; Framingham, MA, USA) or an electrospray ionization time-of-flight mass spectrometer (ESI-TOF-MS; model: JMS-T100LC; JEOL, Tokyo, Japan) was performed by the Mass Spectrometry Lab at GE Global Research (Niskayuna, NY, USA). Human ovarian cancer SKOV3 and MDA-MB-435 melanoma cell lines were obtained from the American Type Tissue Culture Collection (Manassas, VA, USA). Female athymic nude mice (nu/nu) were purchased from Charles River Laboratories (Boston, MA, USA).
Synthesis of Bifunctional Chelator Mal-DOTA
To a solution of DOTA-mono-NHS-tris(tBu)ester (200 mg, 0.248 mmol), triethylamine (70µL, 0.5 mmol) and N-(2-aminoethyl) maleimide TFA salt (42 mg, 0.165 mmol) in anhydrous dichloromethane (2 mL) were added. After stirring at room temperature overnight, the reaction mixture was partitioned between ethyl acetate (25 mL) and water (25 mL). The aqueous layer was separated and extracted with ethyl acetate (3×25 mL). The combined organic layers were washed with water (25 mL) and brine (25 mL), dried over anhydrous magnesium sulfate, and filtered. The filtrate was concentrated and purified by column chromatography using 2% dichloromethane in methanol as the eluent to give the product Mal-DOTA tri-butyl ester (33 mg, 29% of theory, compound 2 in Fig. 1 ). Subsequently, to a solution of Mal-DOTA tri-butyl ester (18.4 mg, 0.0265 mmol) in anhydrous dichloromethane (0.2 mL), triisopropylsilane (25µL, mmol) and TFA (0.8 mL) were added. The reaction mixture was stirred at room temperature overnight and the solvent was removed under vacuum to give the product 3 in quantitative yield (17 mg 2 ] was dissolved with freshly degassed phosphate buffer (pH7.4) at a concentration of 1 mg/mL. The disulfide linkage in the Affibody was reduced by the addition of DTT to a 20-mM concentration. The reaction mixture was incubated for 2 h and eluted through a NAP-5 column (GE Healthcare, Piscataway, NJ, USA) to remove excess of DTT reagent. The column had been previously equilibrated with degassed phosphate buffer, which was the same buffer used for elution of the Affibody. The reduced Affibody was collected and the bifunctional chelator, Mal-DOTA, was added (5-20 equivalents per equivalent of the Affibody) as a solution in DMSO. After mixing with vortex for 2 h, the reaction mixture was dialyzed overnight using Slide-A-Lyzer cassette of molecular weight (MW) cutoff (MWCO) 3.5 kDa (Pierce Biotechnology, Rockford, IL, USA) and MilliQ water as exchange solvent. The dialyzed sample was concentrated using Microcon or Amicon Ultra centrifuge filters MWCO 5 kDa (Millipore, Billerica, MA, USA). Characterization of the bioconjugated products was confirmed using MALDI-TOF-MS or liquid chromatography-ESI-MS (LC-ESI-MS). The purities of the bioconjugates were confirmed by HPLC.
In Vitro Biacore Analysis of Affibody Bioconjugates
Binding interactions between the bioconjugates [DOTA-Z HER2:477 and DOTA-(Z HER2:477 ) 2 ] and HER2/neu antigen were measured in vitro using surface plasmon resonance (SPR) detection on a Biacore™ 3000 instrument (GE Healthcare, Piscataway, NJ, USA). The extracellular domain of the HER2/neu antigen was obtained as a conjugate with the Fc region of human IgG (Fc-Her2) from R&D Systems (Minneapolis, MN, USA) and covalently attached to a CM-5 dextran-functionalized sensor chip (GE Healthcare, Piscataway, NJ, USA) pre-equilibrated with HBS-EP buffer (0.01 M 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid, pH7.4, 0.15 M NaCl, 3 mM ethylenediaminetetraacetic acid, 0.005% v/v surfactant P20) at 10μL/min and subsequently activated with EDC and NHS. The Fc-HER2 (5μg/mL) in 10 mM sodium acetate (pH5.5) was injected onto the activated sensor chip until the desired immobilization level (~3,000 resonance units) was achieved (2 min). Residual activated groups on the sensor chip were blocked by injection of ethanolamine (1 M, pH8.5). Any noncovalently bound conjugates were removed by repeated (5×) washing with 2.5 M NaCl and 50 mM NaOH. A second flow cell on the same sensor chip was treated identically, except with no Fc-HER2 immobilization, in order to serve as a control surface for refractive index changes and nonspecific binding interactions with the sensor chip. Prior to the kinetic study, binding of the target analyte was tested on both surfaces and a surface stability experiment was performed to ensure adequate removal of the bound analyte and regeneration of the sensor chip following treatment with 2.5 M NaCl and 50 mM NaOH. SPR sensorgrams were analyzed using the BIAevaluation software (GE Healthcare, Piscataway, NJ, USA). The robustness of the kinetic model was determined by evaluation of the residuals and standard error for each of the calculated kinetic parameters, the "goodness of the fit" (χ 2 G10), and a direct comparison of the modeled sensorgrams to the experimental data. SPR measurements were collected at eight analyte concentrations (0-100 nM peptide) and the resulting sensorgrams were fitted to the Langmuir binding model. buffer followed by a 1-h incubation at 40°C. The radiolabeled complex was then purified by a PD-10 column (GE Healthcare, Piscataway, NJ, USA). The product was washed out by phosphate buffered saline (PBS) and passed through a 0.22-µm Millipore filter into a sterile vial for in vitro and animal experiments. Radioanalytical HPLC was used to analyze the purified 64 Cu-labeled Affibody molecules.
Octanol/Water Partition Coefficient
To determine the lipophilicity of 64 Cu-DOTA-Z HER2:477 and 64 Cu-DOTA-(Z HER2:477 ) 2 , approximately 370 kBq of 64 Cu-labeled complex in 500µL of PBS (pH7.4), was added to 500µL of octanol in an Eppendorf microcentrifuge tube. The resulting biphasic system was mixed vigorously for 10 min and left at room temperature for another 60 min. The two phases were then separated by centrifugation at 2,000×g for 5 min (model 5415R Eppendorf microcentrifuge; Brinkman, Westbury, NY, USA). From each layer, an aliquot of 100µL was removed and counted in a ϒ-counter (Packard Instruments). The partition coefficient (log P) was then calculated as a ratio of counts in the octanol fraction to the counts in the water fraction. The experiment was repeated three times.
Cell Culture SKOV3 cells were cultured in RPMI-1640 medium supplemented with 10% fetal bovine serum (FBS) and 1% penicillin-streptomycin (Invitrogen Life Technologies, Carlsbad, CA, USA). MDA-MB-435 cells were cultured in Leibovitz's L-15 medium with 2 mM Lglutamine supplemented with 0.01 mg/mL insulin, 10% FBS, and 1% penicillin-streptomycin in a sealed flask. All the cell lines were maintained in a humidified atmosphere of 5% CO 2 at 37°C, with the medium changed every other day. A confluent monolayer was detached with trypsin and dissociated into a single cell suspension for further cell culture.
HER2 Western Analysis of Tumor Cells and Tissues
Expression of HER2 was verified in SKOV3 and MDA-MB-435 cells and tumor samples. Cells were harvested, washed twice with ice-cold PBS once, and lysed in 1× passive cell lysis buffer (Cell signaling, Danvers, MA, USA) for 10 min on ice. Estimated equal amount of the lysates were loaded in 7.5% Tris-HCl ReadyGel (BioRad, Hercules, CA, USA) and transferred onto nitrocellulose membrane (GE Healthcare, Piscataway, NJ, USA) with a semidry blotting system. The blots were probed with rabbit anti-HER2 antibody (Invitrogen, Carlsbad, CA, USA). The α-tubulin antibody was used as a loading control. Xenografted SKOV3 and MDA-MB-435 tumors were harvested and immediately frozen in dry ice. Sodium dodecyl sulfate (SDS) lysis buffer (50 mM Tris, pH7.4, 2% SDS) containing Complete Mini protease inhibitor (Roche, Palo Alto, CA, USA) was used to lyse the tumors. After freezing at −80°C and thawing at 37°C three times, tumor lysates were centrifuged, and supernatant was used for protein detection as described above.
Biodistribution Studies
All animal studies were carried out in compliance with Federal and local institutional rules for the conduct of animal experimentation.
Approximately 1×10
6 SKOV3 cells suspended in Matrigel (BD Biosciences, San Jose, CA, USA) were implanted subcutaneously in the flanks of nude mice. Tumors were grown to a size of 500 to 750 mg (2-3 weeks), and the tumor bearing mice were subject to in vivo biodistribution and imaging studies. For some mice, the mice were first inoculated with 5×10 6 MDA-MB-435 cells. Two to 4 weeks postinoculation, these mice were inoculated with SKOV3 tumor on the other side of the flank.
For biodistribution studies, the SKOV3 tumor-bearing mice (n=3 for each group) were injected with radiolabeled Affibody proteins 64 Cu-DOTA-Z HER2:477 (70-85 μCi, 2.59-3.14 MBq, 0.65-0.79μg) was administrated to the both treated/control tumor mice. At different time p.i., the mice were anesthetized with 2% isoflurane and placed in the prone position and near the center of the field of view of microPET. The 5-min static scans were obtained and the images were reconstructed by a two-dimensional ordered subsets expectation maximum algorithm. The quantification analysis of PET images was then performed using the same method as previously reported [9] .
MicroPET Imaging
Statistical Methods
Statistical analysis was performed using the Student's t test for unpaired data. A 95% confidence level was chosen to determine the significance between groups, with PG0.05 being significantly different.
Results
Chemistry
The maleimide amine linker was used to react with the tributyl protected mono-NHS DOTA chelator (compound 1; Fig. 1 ) under conventional EDC/HOBT activation to form an amide. For the preparation of the compound 3, the carboxylate version of DOTA was also tried using EDC/ HOBT coupling but only starting material was recovered. The desired product (compound 2) was obtained in a 29% yield and verified by ESI-MS and NMR. 
HER2 Binding Affinity of Affibody Bioconjugates
The results of Biacore binding studies of Affibody bioconjugates are shown in Fig. 2 . The binding affinities of DOTA-(Z HER2:477 ) 2 and DOTA-Z HER2:477 were 100 pM and 1.5 nM, respectively (Fig. 2a, b) . The binding affinities of these constructs still remain in a very promising range. The on rates for both DOTA conjugated molecules were very fast, with association constants in the range of 10 5 . In addition, the off rates were very slow, with dissociation constants in the range of 10 −4 -10 −5 , close to the sensitivity limits of the Biacore assay.
HER2 Western Analysis of Tumor Cells and Tissues
The radiolabeled Affibody molecules were then evaluated in the SKOV3 ovarian cancer and MDA-MB-435 melanoma with different HER2 expression. Western blot analysis of HER2 expression in these two cultured tumor cell lines or xenografted tumor samples was performed and the results are shown in Fig. 3 . Obviously, SKOV3 showed good HER2 expression in both cultured cells and tumor samples, while MDA-MB-435 cells and tumor exhibited minimum HER2 expression. Quantification analysis of western gel further revealed that HER2 expression in SKOV3 tumor tissue was 10-15-folds higher than that of MDA-MB-435 tumor.
Biodistribution Studies
Biodistribution data for 64 Cu-labeled DOTA-(Z HER2:477 ) 2 and DOTA-Z HER2:477 at 1, 4, and 20 h are summarized in Table 1. 64 Cu-DOTA-Z HER2:477 exhibited much higher tumor uptake than that of 64 Cu-DOTA-(Z HER2:477 ) 2 at all times (PG0.05). Rapid and moderate activity accumulation in the SKOV3 tumors was also observed for 64 Cu-DOTA-Z HER2:477 at early time point (3.86±0.58% ID/g at 1 h p.i.). Tumor uptake increased to 6.12±1.44% ID/g at 4 h, then the activity was slowly washed out from the tumor, and uptake Cu-labeled Affibody proteins show much higher uptake (% ID/organ) in kidney than that of liver and intestines (data not shown). These data confirmed that 64 Culabeled proteins were mainly cleared via the urinary system. Finally, it was observed that both 64 Cu-DOTA-Z HER2:477 and 64 Cu-DOTA-(Z HER2:477 ) 2 displayed relatively low uptake in all other normal organs.
DOTA-Z HER2
MicroPET Imaging
Decay-corrected coronal microPET images of a mouse bearing SKOV3 and MDA-MB-435 tumor at 1, 4, and 20 h after tail vein injection of 64 Cu-DOTA-Z HER2:477 or 64 Cu-DOTA-(Z HER2:477 ) 2 are shown in Fig. 4a and b , respectively. For 64 Cu-DOTA-(Z HER2:477 ) 2 , SKOV3 tumor was visible but with moderate tumor-to-background contrast. However, MDA-MB-435 tumor showed very poor uptake and hence low tumor-to-background contrast. For 64 Cu-DOTA-Z HER2:477 , SKOV3 tumor was clearly visualized with good tumor-to-background contrast at 1 to 20 h p.i. Low uptake in MDA-MB-435 tumor was also observed, making it very difficult to visualize the tumor. High activity accumulation was also observed in the kidney for both tracers, which was consistent with the finding from the biodistribution study.
In order to understand the relationship between the 64 Cu-DOTA-Z HER2:477 Affibody and a well-accepted HER2-targeting agent, Herceptin, and potentially specificity of the Affibody for HER2, mice bearing SKOV3 tumor (n=3) were first treated with 300µg of Herceptin or PBS via tail vein injection. At 48 h, the treated/control tumor mice were injected with 64 Cu-DOTA-Z HER2:477 and then imaged using microPET (Fig. 4c, d for control and treated animal, respectively). Pretreatment of SKOV3 tumor mice with HER2 binding protein (Herceptin) specifically reduced the uptake of 64 Cu-DOTA-Z HER2:477 in the tumor at 1, 3.5, and 24 h, resulting in a lower tumor to background ratios (Fig. 4d) . MicroPET image region of interest quantification analysis was further performed and results are shown in 
Discussion
Affibody proteins, dimeric (Z HER2:477 ) 2 and monomeric Z HER2:477 , were selected for 64 Cu radiolabeling because Affibody has been demonstrated to be a promising platform for developing probes to a variety of targets [3, 4] . By taking advantage of well-established maleimide-sulfhydryl chemistry [16] , the maleimide-functionalized chelator, Mal-DOTA, was prepared in good yield and site specifically conjugated to the C terminus cysteine residue of (Z HER2:477 ) 2 and Z HER2:477 . Therefore, the Affibody proteins can be labeled with radiometals. The radiolabeling strategy described here is the same as the one reported previously [16] . Chelator Mal-DOTA was used in both studies for sitespecific conjugation with the thiol group in the cysteine that is at the C terminus of Affibody. However, different clones of Affibodies were used in these two studies. Monomeric and dimeric Z HER2:477 which are commercially available were used in this study, while Z HER2:342 and H6-Z HER2:342 were used in the literature [16] . Other nonsite-specific radiolabeling methods have also been reported [18, 23] , where the lysine groups in the Affibody were used for radiolabeling. However, these approaches may generate heterogeneous products with reduced capacity because of the multiple lysine residues present in the Affibody including some which are responsible for receptor recognition. To the contrary, the site-specific conjugation of Mal-DOTA provides a pure homogenous product. Biacore analysis of the binding affinities of Affibody bioconjugates reveals that DOTA conjugated (Z HER2:477 ) 2 and Z HER2:477 preserve high binding affinities to HER2 (in pico-and low nanomolar range). Because (Z HER2:477 ) 2 and Z HER2:477 are large molecules and the binding residues are far away from the C terminus, it would be expected that modification of the C terminus cysteine with a relatively small metal chelator would be unlikely to interfere with the binding of the proteins.
64 Cu-labeled dimer and monomer exhibit rapid tumor accumulation and blood clearance, which are the major advantages of using these relatively small synthetic proteins as imaging agents compared to large long circulating proteins such as full antibodies. Furthermore, it was found that although DOTA-conjugated dimer exhibited higher HER2 binding affinity than that of monomer, dimer showed much lower SKOV3 tumor accumulation and tumor-to-normal organ ratios than that of radiolabeled monomer. This finding is in consistent with the in vivo distribution patterns of different clones of anti-HER2 Affibody proteins labeled with radioiodine [23, 30] .
Obviously, 64 Cu-labeled monomer could be used as a lead candidate for further HER2 imaging studies. This result clearly demonstrates that the binding affinity of a probe is not the only factor determining its tumor localization; other properties of the probe such as size, lipophilicity, and charge likely also play important roles for the probe's in vivo biological behavior. Many Affibody analogs with different properties (affinity, size, charge, and lipophilicity) are being synthesized in our laboratories and further evaluated in animal models, in order to understand what causes the difference. Relatively high liver uptake and moderate retention are also observed for the 64 Cu-labeled dimer and monomer. The increased liver uptake over time is likely due to the release of uncoordinated 64 Cu from radiolabeled protein by decomposition in the blood or transchelation in the liver [31] . Lastly, the 64 Cu-labeled dimer exhibits better tumor retention that that of monomer. The tumor uptake of the dimer at 4 and 24 h p.i. maintain the same level (1.46% vs 1.53% ID/g, P>0.05), while a significant amount of activity for monomer is washed out from the tumor (6.12% vs 3.65% ID/g). This is likely caused by the lower binding affinity of monomer.
Very high kidney uptake and retention are observed for 64 Cu-labeled Affibody molecules. The radiation dose to the kidney, a radiation-sensitive organ, may likely be a concern if the particularly high-energy 64 Cu probe is used in clinic. Further optimization of the probe for achieving better tumor targeting and pharmacokinetic properties are under active investigation in our laboratories, in order to eventually move the Affibody-based probe into clinical HER2 imaging. Several strategies in the peptide/antibody-based imaging field may be applied to reduce the relatively high kidney uptake: (1) modification of the amino acid sequence of the Affibody to modulate the surface charge, lipophilicity, and binding affinity of the protein, which may also include PEGylation, (2) coinjection of cold amino acids such as lysine, which is an established method in the field of peptide based radioimaging/radiotherapy for reducing the kidney uptake, (3) use of cleavable linkers specific to mechanisms in the kidney, and (4) use of different radioisotopes such as radiohalogens, etc. Indeed, it is found that 18 F-labeled Affibody molecules show much lower kidney uptake and retention [9, 11] . Furthermore, a recent study also demonstrates that the kidney uptake of 99m Tc-labeled Affibodies can be dramatically reduced by carefully selection of the amino acid chelators [32] . Overall, it is likely that kidney uptake and retention of the radiolabeled Affibodies could be minimized.
MicroPET imaging and quantification analysis of 64 Culabeled (Z HER2:477 ) 2 and Z HER2:477 in mice bearing SKOV3 and MDA-MB-435 tumor at 1, 4, and 20 h after tail vein injection reveal good SKOV3 tumor-to-background ratio for 64 Cu-DOTA-Z HER2:477 , while 64 Cu-DOTA-(Z HER2:477 ) 2 SKOV3 tumor-to-background ratio is low (Fig. 4a, b) . The clear tumor PET imaging of 64 Cu-DOTA-Z HER2:477 at as early as 1 h p.i. apparently indicates the rapid tumor accumulation and fast normal organ clearance of monomeric Affibody molecule. Furthermore, both tracers display low uptake in the MDA-MB-435 tumor with low HER2 expression. These results are consistent with the findings obtained from the biodistribution studies. Moreover, the specificity of 64 Cu-DOTA-Z HER2:477 is demonstrated by the reduced SKOV3 tumor uptake in the mice which were pretreated with HER2 binding antibody, Herceptin. This result does potentially vary from the published literature [17] . Possible reasons for our results include (1) different clones of anti-HER2 Affibody molecules used in these two studies and thus uncommon epitope between them, (2) steric hindrance from the Herceptin antibody, or (3) internalization of HER2 upon Herceptin binding and inaccessibility to the Affibody [33] .
Overall, 64 Cu-DOTA-Z HER2:477 microPET imaging is a potential strategy for not only detection HER2-positive tumors but also differentiation tumors with different HER2 expression in living subjects. It is also noteworthy to point out that the anti-HER2 Affibody molecule Z HER2:342 labeled with 68 Ga and 111
In have been used in imaging human breast cancer patients, indicating the low immunogenicity of this molecular probe derived from staphylococcal protein A [22] .
Conclusion
Site-specific 64 Cu-labeled Z HER2:477 and (Z HER2:477 ) 2 have been synthesized. Biodistribution and microPET imaging studies further demonstrate that 64 Cu-labeled Z HER2:477 is a promising molecular probe for imaging HER2 receptor expression in living mice. Strategies to further improve the labeling and biodistribution of the Affibody molecule and Affibody molecules against other targets are also under investigation. Affibody-based probes can likely be translated into multiple imaging and disease applications.
